An anti-PD-L1 nanobody fused to either interleukin-2 (IL-2) or interferon-γ (IFNγ) demonstrated in vivo efficacy in treatment-resistant pancreatic tumors (141). Here, IL2 is linked to pancreatic neoplasm.